Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 13c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.64), $0.13 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $97.9 thousand, versus $30.66 thousand reported last year.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• BofA lists top 5 themes driving next $1tn in incremental semi sales